Bimekizumab History and Updates

195 events · 2015 – present

Synced daily from openFDA and ClinicalTrials.gov. Last sync: June 18, 2026.

FDA Approvals

Label Revisions

183

Trial Milestones

Pivotal Publications

Source: openFDA, ClinicalTrials.gov via AACT, PubMed · Hipa.ai, 2026-06-08Download chart as PNG

This page tracks every FDA action, clinical trial milestone, and major publication for Bimekizumab since 2015, drawn from openFDA, ClinicalTrials.gov, and PubMed.

All published updates (16)

2026

Primary completionBimekizumab Phase 3 Trial for Psoriatic Arthritis Reaches Primary Completion· May 26, 2026
Primary completionBimekizumab Phase 3 Trial for Psoriatic Arthritis Reaches Primary Completion· May 25, 2026
Results postedBimekizumab Phase 2 PK Results in Adolescent Plaque Psoriasis Posted· May 18, 2026
Results postedBimekizumab Phase 3 for Plaque Psoriasis Shows 94% PASI90 Response· Feb 20, 2026
Primary completionBimekizumab Phase 3 Trial for Psoriatic Arthritis Reaches Primary Completion· Feb 6, 2026

2025

Results postedBimekizumab Bioequivalence Study Shows Similar PK for Different Injection…· Apr 10, 2025
Results postedBimekizumab Bioequivalence Study Shows Similar PK for Autoinjector Formulations· Apr 10, 2025
Primary completionBimekizumab Phase 3 for Plaque Psoriasis Achieves 94% PASI90 Response· Feb 5, 2025

2024

Pivotal publicationBimekizumab Efficacy and Safety Data Published for Hidradenitis Suppurativa· Jan 1, 2024

2023

Pivotal publicationBimekizumab for Psoriatic Arthritis: Efficacy and Safety Study Published· Jan 1, 2023
Pivotal publicationBimekizumab Phase 3 Trial for Psoriatic Arthritis Naive Patients Published· Jan 1, 2023

2022

Primary completionBimekizumab Phase 3 for Hidradenitis Suppurativa Shows Improved HiSCR50· Apr 7, 2022

2021

Primary completionBimekizumab Phase 3 for Hidradenitis Suppurativa Shows Improved HiSCR50· Nov 9, 2021
Pivotal publicationBimekizumab Shows Comparative Data Against Adalimumab in Plaque Psoriasis· Jan 1, 2021
Pivotal publicationBimekizumab Shows Efficacy and Safety vs. Ustekinumab for Moderate to Severe…· Jan 1, 2021
Pivotal publicationBimekizumab Shows Efficacy and Safety in Moderate to Severe Plaque Psoriasis· Jan 1, 2021

Upcoming & expected milestones

Trial startedJul 1, 2026· ClinicalTrials.gov

Phase 4 trial started: NCT07497620

Bimzelx (Bimekizumab) For The Treatment Of Adult Onset PRP

Primary completionJul 28, 2026· ClinicalTrials.gov

Phase 3 primary completion: NCT04901195

A Study to Test the Long-term Treatment of Bimekizumab in Study Participants With Moderate to Severe Hidradenitis Suppurativa

Trial startedAug 1, 2026· ClinicalTrials.gov

Phase 4 trial started: NCT07352566

Utilization of a Microdevice for Psoriasis and Atopic Dermatitis

Primary completionAug 7, 2026· ClinicalTrials.gov

Phase 3 primary completion: NCT04436640

A Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Bimekizumab in Subjects With Active Axial Spondyloarthritis Including

Primary completionDec 21, 2026· ClinicalTrials.gov

Phase 3 primary completion: NCT06921850

A Study to Assess the Pharmacokinetics and Safety of Bimekizumab in Children and Adolescents With Moderate to Severe Hidradenitis Suppurativ

Primary completionFeb 28, 2027· ClinicalTrials.gov

Primary completion: NCT06786936

Evaluating the Role of IL-17 as an Orchestrator of Peripheral-central Cross Talk in Depressive Symptoms

Primary completionMar 9, 2027· ClinicalTrials.gov

Phase 3 primary completion: NCT06506916

A Study to Evaluate the Effect of Bimekizumab on Gene Expression Biomarkers in Study Participants With Moderate to Severe Plaque Psoriasis

Primary completionMay 3, 2027· ClinicalTrials.gov

Phase 1 primary completion: NCT06888193

A Study to Assess the Concentration of Bimekizumab in Mature Breast Milk From Mothers Receiving Treatment With Bimzelx® (Bimekizumab)

Primary completionAug 1, 2027· ClinicalTrials.gov

Phase 4 primary completion: NCT07497620

Bimzelx (Bimekizumab) For The Treatment Of Adult Onset PRP

Primary completionSep 30, 2027· ClinicalTrials.gov

Phase 2 primary completion: NCT07138898

Immunosuppressant Management in Rheumatology Patients Undergoing Elective Total Shoulder Arthroplasty

Primary completionDec 27, 2027· ClinicalTrials.gov

Phase 3 primary completion: NCT07219420

A Study to Evaluate the Efficacy and Safety of Bimekizumab in Study Participants With Palmoplantar Pustulosis

Primary completionApr 12, 2028· ClinicalTrials.gov

Phase 3 primary completion: NCT06668181

An Open-label Study to Evaluate the Pharmacokinetics and Safety of Bimekizumab in Pediatric Study Participants With Active Juvenile Idiopath

Primary completionMay 18, 2028· ClinicalTrials.gov

Phase 1 primary completion: NCT07290036

A Study to Learn if Bimekizumab Given in Different Ways is Safe and Moves Similarly Throughout the Body Over Time in Adults

Primary completionJul 22, 2028· ClinicalTrials.gov

Phase 2 primary completion: NCT06742333

Early Intervention in Plaque Psoriasis: is Bimekizumab Able to Delay Chronic Inflammation?

Primary completionAug 21, 2028· ClinicalTrials.gov

Phase 3 primary completion: NCT06425549

A Study to Evaluate the Efficacy and Safety of Bimekizumab Compared to Ustekinumab in Children and Adolescents From 6 Years to Less Than 18

Primary completionJun 1, 2030· ClinicalTrials.gov

Phase 4 primary completion: NCT07352566

Utilization of a Microdevice for Psoriasis and Atopic Dermatitis

Past events

2026

Primary completionMay 26, 2026· ClinicalTrials.gov

Phase 3 primary completion: NCT04009499

A Study to Assess the Long-term Safety, Tolerability, and Efficacy of Bimekizumab in the Treatment of Subjects With Active Psoriatic Arthrit

Primary completionMay 25, 2026· ClinicalTrials.gov

Phase 3 primary completion: NCT04009499

A Study to Assess the Long-term Safety, Tolerability, and Efficacy of Bimekizumab in the Treatment of Subjects With Active Psoriatic Arthrit

Results postedMay 18, 2026· ClinicalTrials.gov

Trial results posted: NCT04718896

A Study to Assess the Pharmacokinetics, Safety, and Efficacy of Two Doses of Bimekizumab in Adolescent Study Participants With Moderate to S

Trial registeredMar 27, 2026· ClinicalTrials.gov

Phase 4 trial registered on ClinicalTrials.gov: NCT07497620

Bimzelx (Bimekizumab) For The Treatment Of Adult Onset PRP

Primary completionMar 17, 2026· ClinicalTrials.gov

Phase 4 primary completion: NCT06336343

Bimekizumab in Plaque Psoriasis

Results postedFeb 20, 2026· ClinicalTrials.gov

Trial results posted: NCT06011733

A Study to Evaluate the Efficacy and Safety of Bimekizumab in Chinese Adult Study Participants With Moderate to Severe Plaque Psoriasis

Primary completionFeb 6, 2026· ClinicalTrials.gov

Phase 3 primary completion: NCT06624228

A Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Study Participants With Active Psoriatic Arthritis

Trial registeredJan 20, 2026· ClinicalTrials.gov

Phase 4 trial registered on ClinicalTrials.gov: NCT07352566

Utilization of a Microdevice for Psoriasis and Atopic Dermatitis

Trial startedJan 1, 2026· ClinicalTrials.gov

Phase 4 trial started: NCT07352566

Utilization of a Microdevice for Psoriasis and Atopic Dermatitis

2025

Trial registeredDec 17, 2025· ClinicalTrials.gov

Phase 1 trial registered on ClinicalTrials.gov: NCT07290036

A Study to Learn if Bimekizumab Given in Different Ways is Safe and Moves Similarly Throughout the Body Over Time in Adults

Trial startedDec 10, 2025· ClinicalTrials.gov

Phase 1 trial started: NCT07290036

A Study to Learn if Bimekizumab Given in Different Ways is Safe and Moves Similarly Throughout the Body Over Time in Adults

Trial startedNov 14, 2025· ClinicalTrials.gov

Phase 3 trial started: NCT07219420

A Study to Evaluate the Efficacy and Safety of Bimekizumab in Study Participants With Palmoplantar Pustulosis

Trial startedNov 5, 2025· ClinicalTrials.gov

Phase 1 trial started: NCT06888193

A Study to Assess the Concentration of Bimekizumab in Mature Breast Milk From Mothers Receiving Treatment With Bimzelx® (Bimekizumab)

Trial registeredOct 21, 2025· ClinicalTrials.gov

Phase 3 trial registered on ClinicalTrials.gov: NCT07219420

A Study to Evaluate the Efficacy and Safety of Bimekizumab in Study Participants With Palmoplantar Pustulosis

Trial startedSep 30, 2025· ClinicalTrials.gov

Phase 2 trial started: NCT07138898

Immunosuppressant Management in Rheumatology Patients Undergoing Elective Total Shoulder Arthroplasty

Trial registeredAug 24, 2025· ClinicalTrials.gov

Phase 2 trial registered on ClinicalTrials.gov: NCT07138898

Immunosuppressant Management in Rheumatology Patients Undergoing Elective Total Shoulder Arthroplasty

Trial startedJul 22, 2025· ClinicalTrials.gov

Phase 2 trial started: NCT06742333

Early Intervention in Plaque Psoriasis: is Bimekizumab Able to Delay Chronic Inflammation?

Trial startedJun 2, 2025· ClinicalTrials.gov

Trial started: NCT06786936

Evaluating the Role of IL-17 as an Orchestrator of Peripheral-central Cross Talk in Depressive Symptoms

Results postedApr 10, 2025· ClinicalTrials.gov

Trial results posted: NCT04255862

A Study to Evaluate the Bioequivalence of Bimekizumab Given as 1x2mL or 2x1mL Subcutaneous Injection in Healthy Study Participants

Results postedApr 10, 2025· ClinicalTrials.gov

Trial results posted: NCT05292131

A Bioequivalence Study of Bimekizumab Given as 1x2mL or 2x1mL Subcutaneous Injection Using an Autoinjector in Healthy Study Participants

Trial registeredApr 10, 2025· ClinicalTrials.gov

Phase 3 trial registered on ClinicalTrials.gov: NCT06921850

A Study to Assess the Pharmacokinetics and Safety of Bimekizumab in Children and Adolescents With Moderate to Severe Hidradenitis Suppurativ

Trial startedApr 7, 2025· ClinicalTrials.gov

Phase 3 trial started: NCT06921850

A Study to Assess the Pharmacokinetics and Safety of Bimekizumab in Children and Adolescents With Moderate to Severe Hidradenitis Suppurativ

Trial registeredMar 21, 2025· ClinicalTrials.gov

Phase 1 trial registered on ClinicalTrials.gov: NCT06888193

A Study to Assess the Concentration of Bimekizumab in Mature Breast Milk From Mothers Receiving Treatment With Bimzelx® (Bimekizumab)

Primary completionMar 12, 2025· ClinicalTrials.gov

Phase 2 primary completion: NCT04718896

A Study to Assess the Pharmacokinetics, Safety, and Efficacy of Two Doses of Bimekizumab in Adolescent Study Participants With Moderate to S

Trial startedMar 11, 2025· ClinicalTrials.gov

Phase 3 trial started: NCT06668181

An Open-label Study to Evaluate the Pharmacokinetics and Safety of Bimekizumab in Pediatric Study Participants With Active Juvenile Idiopath

Primary completionFeb 5, 2025· ClinicalTrials.gov

Phase 3 primary completion: NCT06011733

A Study to Evaluate the Efficacy and Safety of Bimekizumab in Chinese Adult Study Participants With Moderate to Severe Plaque Psoriasis

Primary completionJan 30, 2025· ClinicalTrials.gov

Phase 4 primary completion: NCT04340076

Dose Reduction of IL17 and IL23 Inhibitors in Psoriasis

Trial registeredJan 22, 2025· ClinicalTrials.gov

Trial registered on ClinicalTrials.gov: NCT06786936

Evaluating the Role of IL-17 as an Orchestrator of Peripheral-central Cross Talk in Depressive Symptoms

Results postedJan 9, 2025· ClinicalTrials.gov

Trial results posted: NCT04242446

A Study to Evaluate the Efficacy and Safety of Bimekizumab in Study Participants With Moderate to Severe Hidradenitis Suppurativa

2024

Trial registeredDec 19, 2024· ClinicalTrials.gov

Phase 2 trial registered on ClinicalTrials.gov: NCT06742333

Early Intervention in Plaque Psoriasis: is Bimekizumab Able to Delay Chronic Inflammation?

Results postedDec 6, 2024· ClinicalTrials.gov

Trial results posted: NCT03598790

A Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis

Results postedDec 5, 2024· ClinicalTrials.gov

Trial results posted: NCT04242498

A Study to Evaluate the Efficacy and Safety of Bimekizumab in Study Participants With Moderate to Severe Hidradenitis Suppurativa

FDA approval (supplemental)Nov 19, 2024· FDA

FDA approved supplemental application for Bimzelx (bimekizumab) — Efficacy (BLA 761151 S-10)

Sponsor: UCB INC. Class: Efficacy.

Results postedNov 13, 2024· ClinicalTrials.gov

Trial results posted: NCT03928704

A Study to Evaluate the Efficacy and Safety of Bimekizumab in Subjects With Active Nonradiographic Axial Spondyloarthritis

Results postedNov 13, 2024· ClinicalTrials.gov

Trial results posted: NCT03355573

A Study to Evaluate the Long Term Safety and Efficacy of Bimekizumab in Subjects With Ankylosing Spondylitis

Trial registeredOct 31, 2024· ClinicalTrials.gov

Phase 3 trial registered on ClinicalTrials.gov: NCT06668181

An Open-label Study to Evaluate the Pharmacokinetics and Safety of Bimekizumab in Pediatric Study Participants With Active Juvenile Idiopath

Results postedOct 23, 2024· ClinicalTrials.gov

Trial results posted: NCT03895203

A Study to Test the Efficacy and Safety of Bimekizumab in the Treatment of Subjects With Active Psoriatic Arthritis

Trial startedOct 21, 2024· ClinicalTrials.gov

Phase 3 trial started: NCT06624228

A Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Study Participants With Active Psoriatic Arthritis

Results postedOct 16, 2024· ClinicalTrials.gov

Trial results posted: NCT03896581

A Study to Evaluate the Efficacy and Safety of Bimekizumab in the Treatment of Subjects With Active Psoriatic Arthritis

FDA approval (supplemental)Oct 11, 2024· FDA

FDA approved supplemental application for Bimzelx (bimekizumab) — Efficacy (BLA 761151 S-9)

Sponsor: UCB INC. Class: Efficacy.

Results postedOct 10, 2024· ClinicalTrials.gov

Trial results posted: NCT03928743

A Study to Evaluate the Efficacy and Safety of Bimekizumab in Subjects With Active Ankylosing Spondylitis

Trial registeredOct 2, 2024· ClinicalTrials.gov

Phase 3 trial registered on ClinicalTrials.gov: NCT06624228

A Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Study Participants With Active Psoriatic Arthritis

FDA approval (supplemental)Sep 20, 2024· FDA

FDA approved supplemental application for Bimzelx (bimekizumab) — Efficacy (BLA 761151 S-5)

Sponsor: UCB INC. Class: Efficacy.

FDA approval (supplemental)Sep 20, 2024· FDA

FDA approved supplemental application for Bimzelx (bimekizumab) — Efficacy (BLA 761151 S-7)

Sponsor: UCB INC. Class: Efficacy.

FDA approval (supplemental)Sep 20, 2024· FDA

FDA approved supplemental application for Bimzelx (bimekizumab) — Efficacy (BLA 761151 S-6)

Sponsor: UCB INC. Class: Efficacy.

Trial startedJul 29, 2024· ClinicalTrials.gov

Phase 3 trial started: NCT06506916

A Study to Evaluate the Effect of Bimekizumab on Gene Expression Biomarkers in Study Participants With Moderate to Severe Plaque Psoriasis

Trial registeredJul 18, 2024· ClinicalTrials.gov

Phase 3 trial registered on ClinicalTrials.gov: NCT06506916

A Study to Evaluate the Effect of Bimekizumab on Gene Expression Biomarkers in Study Participants With Moderate to Severe Plaque Psoriasis

Trial startedJun 25, 2024· ClinicalTrials.gov

Phase 3 trial started: NCT06425549

A Study to Evaluate the Efficacy and Safety of Bimekizumab Compared to Ustekinumab in Children and Adolescents From 6 Years to Less Than 18

Trial startedJun 3, 2024· ClinicalTrials.gov

Phase 4 trial started: NCT06336343

Bimekizumab in Plaque Psoriasis

Trial registeredMay 22, 2024· ClinicalTrials.gov

Phase 3 trial registered on ClinicalTrials.gov: NCT06425549

A Study to Evaluate the Efficacy and Safety of Bimekizumab Compared to Ustekinumab in Children and Adolescents From 6 Years to Less Than 18

Trial registeredMar 28, 2024· ClinicalTrials.gov

Phase 4 trial registered on ClinicalTrials.gov: NCT06336343

Bimekizumab in Plaque Psoriasis

Results postedMar 22, 2024· ClinicalTrials.gov

Trial results posted: NCT05020249

A Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Korean Study Participants With Moderate to Severe Plaque Psoriasis

Pivotal publicationJan 1, 2024· PubMed

Efficacy and safety of bimekizumab in patients with moderate-to-severe hidradenitis suppurativa (BE HEARD I and BE HEARD II): two 48-week, randomised, double-bl (Lancet)

BE HEARD II — A Study to Evaluate the Efficacy and Safety of Bimekizumab in Study Participants With Moderate to Severe Hidradenitis Suppurativa

2023

Results postedDec 1, 2023· ClinicalTrials.gov

Trial results posted: NCT03347110

A Study to Evaluate the Long-Term Safety and Efficacy of Bimekizumab in Subjects With Psoriatic Arthritis

Results postedNov 30, 2023· ClinicalTrials.gov

Trial results posted: NCT04109976

A Study to Evaluate the Safe and Effective Use of the Prefilled Safety Syringe or the Auto-injector for the Subcutaneous Self-injection of B

Primary completionNov 14, 2023· ClinicalTrials.gov

Phase 3 primary completion: NCT03598790

A Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis

Trial startedOct 31, 2023· ClinicalTrials.gov

Phase 3 trial started: NCT06011733

A Study to Evaluate the Efficacy and Safety of Bimekizumab in Chinese Adult Study Participants With Moderate to Severe Plaque Psoriasis

FDA approvalOct 17, 2023· FDA

FDA approved Bimzelx (bimekizumab) (BLA 761151)

Sponsor: UCB INC. Class: Type 1 - New Molecular Entity and Type 4 - New Combination.

Primary completionSep 30, 2023· ClinicalTrials.gov

Phase 4 primary completion: NCT05499416

Effect of Bimekizumab in Patients With Psoriasis Vulgaris and Active Psoriatic Arthritis

Trial registeredAug 25, 2023· ClinicalTrials.gov

Phase 3 trial registered on ClinicalTrials.gov: NCT06011733

A Study to Evaluate the Efficacy and Safety of Bimekizumab in Chinese Adult Study Participants With Moderate to Severe Plaque Psoriasis

Results postedAug 8, 2023· ClinicalTrials.gov

Trial results posted: NCT03766685

A Study to Evaluate the Safe and Effective Use of the Prefilled Safety Syringe or the Auto-injector for the Subcutaneous Self-injection of B

Results postedJul 27, 2023· ClinicalTrials.gov

Trial results posted: NCT03215277

A Study to Test the Efficacy and Safety of Bimekizumab and Certolizumab Pegol in Patients With Active Ankylosing Spondylitis

Trial startedJan 31, 2023· ClinicalTrials.gov

Phase 4 trial started: NCT05499416

Effect of Bimekizumab in Patients With Psoriasis Vulgaris and Active Psoriatic Arthritis

Primary completionJan 9, 2023· ClinicalTrials.gov

Phase 1 primary completion: NCT05292131

A Bioequivalence Study of Bimekizumab Given as 1x2mL or 2x1mL Subcutaneous Injection Using an Autoinjector in Healthy Study Participants

Pivotal publicationJan 1, 2023· PubMed

Bimekizumab in patients with active psoriatic arthritis and previous inadequate response or intolerance to tumour necrosis factor-α inhibitors: a randomised, do (Lancet)

BE COMPLETE — A Study to Evaluate the Efficacy and Safety of Bimekizumab in the Treatment of Subjects With Active Psoriatic Arthritis

Pivotal publicationJan 1, 2023· PubMed

Bimekizumab in patients with psoriatic arthritis, naive to biologic treatment: a randomised, double-blind, placebo-controlled, phase 3 trial (BE OPTIMAL). (Lancet)

BE OPTIMAL — A Study to Test the Efficacy and Safety of Bimekizumab in the Treatment of Subjects With Active Psoriatic Arthritis

2022

Primary completionOct 19, 2022· ClinicalTrials.gov

Phase 2 primary completion: NCT03355573

A Study to Evaluate the Long Term Safety and Efficacy of Bimekizumab in Subjects With Ankylosing Spondylitis

Results postedOct 10, 2022· ClinicalTrials.gov

Trial results posted: NCT03536884

A Study to Evaluate the Efficacy and Safety of Bimekizumab Compared to an Active Comparator in Adult Subjects With Moderate to Severe Chroni

Primary completionSep 5, 2022· ClinicalTrials.gov

Phase 3 primary completion: NCT05020249

A Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Korean Study Participants With Moderate to Severe Plaque Psoriasis

Trial registeredAug 12, 2022· ClinicalTrials.gov

Phase 4 trial registered on ClinicalTrials.gov: NCT05499416

Effect of Bimekizumab in Patients With Psoriasis Vulgaris and Active Psoriatic Arthritis

Primary completionJun 29, 2022· ClinicalTrials.gov

Phase 3 primary completion: NCT03928704

A Study to Evaluate the Efficacy and Safety of Bimekizumab in Subjects With Active Nonradiographic Axial Spondyloarthritis

Primary completionApr 7, 2022· ClinicalTrials.gov

Phase 3 primary completion: NCT04242446

A Study to Evaluate the Efficacy and Safety of Bimekizumab in Study Participants With Moderate to Severe Hidradenitis Suppurativa

Results postedMar 31, 2022· ClinicalTrials.gov

Trial results posted: NCT03230292

A Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Bimekizumab in Adult Patients With Chronic Plaque Psoriasis

Trial registeredMar 23, 2022· ClinicalTrials.gov

Phase 1 trial registered on ClinicalTrials.gov: NCT05292131

A Bioequivalence Study of Bimekizumab Given as 1x2mL or 2x1mL Subcutaneous Injection Using an Autoinjector in Healthy Study Participants

Trial startedMar 17, 2022· ClinicalTrials.gov

Phase 1 trial started: NCT05292131

A Bioequivalence Study of Bimekizumab Given as 1x2mL or 2x1mL Subcutaneous Injection Using an Autoinjector in Healthy Study Participants

Results postedMar 4, 2022· ClinicalTrials.gov

Trial results posted: NCT03410992

A Study With a Initial Treatment Period Followed by a Randomized-withdrawal Period to Evaluate the Efficacy and Safety of Bimekizumab in Adu

Results postedMar 2, 2022· ClinicalTrials.gov

Trial results posted: NCT03412747

A Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis

Results postedFeb 9, 2022· ClinicalTrials.gov

Trial results posted: NCT03248531

A Study to Test the Efficacy, Safety and Pharmacokinetics of Bimekizumab in Subjects With Moderate to Severe Hidradenitis Suppurativa.

Results postedFeb 3, 2022· ClinicalTrials.gov

Trial results posted: NCT03370133

A Study to Evaluate the Efficacy and Safety of Bimekizumab Compared to Placebo and an Active Comparator in Adult Subjects With Moderate to S

2021

Primary completionDec 8, 2021· ClinicalTrials.gov

Phase 3 primary completion: NCT03896581

A Study to Evaluate the Efficacy and Safety of Bimekizumab in the Treatment of Subjects With Active Psoriatic Arthritis

Primary completionNov 9, 2021· ClinicalTrials.gov

Phase 3 primary completion: NCT04242498

A Study to Evaluate the Efficacy and Safety of Bimekizumab in Study Participants With Moderate to Severe Hidradenitis Suppurativa

Results postedOct 25, 2021· ClinicalTrials.gov

Trial results posted: NCT03010527

A Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Bimekizumab in Patients With Chronic Plaque Psoriasis

Trial startedSep 27, 2021· ClinicalTrials.gov

Phase 3 trial started: NCT05020249

A Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Korean Study Participants With Moderate to Severe Plaque Psoriasis

Primary completionSep 3, 2021· ClinicalTrials.gov

Phase 3 primary completion: NCT03928743

A Study to Evaluate the Efficacy and Safety of Bimekizumab in Subjects With Active Ankylosing Spondylitis

Trial registeredAug 31, 2021· ClinicalTrials.gov

Phase 1 trial registered on ClinicalTrials.gov: NCT05028127

A Study to Evaluate the Relative Bioavailability and Tolerability of Bimekizumab in Healthy Subjects

Trial registeredAug 25, 2021· ClinicalTrials.gov

Phase 3 trial registered on ClinicalTrials.gov: NCT05020249

A Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Korean Study Participants With Moderate to Severe Plaque Psoriasis

Primary completionAug 17, 2021· ClinicalTrials.gov

Phase 3 primary completion: NCT03895203

A Study to Test the Efficacy and Safety of Bimekizumab in the Treatment of Subjects With Active Psoriatic Arthritis

Trial startedMay 27, 2021· ClinicalTrials.gov

Phase 3 trial started: NCT04901195

A Study to Test the Long-term Treatment of Bimekizumab in Study Participants With Moderate to Severe Hidradenitis Suppurativa

Trial registeredMay 25, 2021· ClinicalTrials.gov

Phase 3 trial registered on ClinicalTrials.gov: NCT04901195

A Study to Test the Long-term Treatment of Bimekizumab in Study Participants With Moderate to Severe Hidradenitis Suppurativa

Primary completionApr 26, 2021· ClinicalTrials.gov

Phase 1 primary completion: NCT04255862

A Study to Evaluate the Bioequivalence of Bimekizumab Given as 1x2mL or 2x1mL Subcutaneous Injection in Healthy Study Participants

Trial startedApr 6, 2021· ClinicalTrials.gov

Phase 2 trial started: NCT04718896

A Study to Assess the Pharmacokinetics, Safety, and Efficacy of Two Doses of Bimekizumab in Adolescent Study Participants With Moderate to S

Trial registeredJan 22, 2021· ClinicalTrials.gov

Phase 2 trial registered on ClinicalTrials.gov: NCT04718896

A Study to Assess the Pharmacokinetics, Safety, and Efficacy of Two Doses of Bimekizumab in Adolescent Study Participants With Moderate to S

Results postedJan 6, 2021· ClinicalTrials.gov

Trial results posted: NCT03025542

A Study to Evaluate the Pharmacokinetics (PK), Pharmacodynamics (PD), and Safety of Bimekizumab in Patients With Chronic Plaque Psoriasis

Pivotal publicationJan 1, 2021· PubMed

Bimekizumab versus Adalimumab in Plaque Psoriasis. (N Engl J Med)

BE SURE — A Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis

Pivotal publicationJan 1, 2021· PubMed

Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blin (Lancet)

BE VIVID — A Study to Evaluate the Efficacy and Safety of Bimekizumab Compared to Placebo and an Active Comparator in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis

Pivotal publicationJan 1, 2021· PubMed

Bimekizumab efficacy and safety in moderate to severe plaque psoriasis (BE READY): a multicentre, double-blind, placebo-controlled, randomised withdrawal phase (Lancet)

BE READY — A Study With a Initial Treatment Period Followed by a Randomized-withdrawal Period to Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis

2020

Results postedNov 25, 2020· ClinicalTrials.gov

Trial results posted: NCT02969525

A Study to Evaluate the Dose Response Based on the Efficacy, Safety and Tolerability of Bimekizumab in Subjects With Active Psoriatic Arthri

Results postedNov 19, 2020· ClinicalTrials.gov

Trial results posted: NCT02905006

Study to Evaluate Safety and Efficacy of Different Doses of Bimekizumab in Patients With Chronic Plaque Psoriasis

Results postedNov 16, 2020· ClinicalTrials.gov

Trial results posted: NCT02963506

A Study to Evaluate the Efficacy and Safety of Different Doses of Bimekizumab in Subjects With Active Ankylosing Spondylitis

Primary completionNov 5, 2020· ClinicalTrials.gov

Phase 3 primary completion: NCT04109976

A Study to Evaluate the Safe and Effective Use of the Prefilled Safety Syringe or the Auto-injector for the Subcutaneous Self-injection of B

Primary completionOct 29, 2020· ClinicalTrials.gov

Phase 2 primary completion: NCT03347110

A Study to Evaluate the Long-Term Safety and Efficacy of Bimekizumab in Subjects With Psoriatic Arthritis

Trial startedAug 20, 2020· ClinicalTrials.gov

Phase 4 trial started: NCT04340076

Dose Reduction of IL17 and IL23 Inhibitors in Psoriasis

Primary completionJul 14, 2020· ClinicalTrials.gov

Phase 3 primary completion: NCT03766685

A Study to Evaluate the Safe and Effective Use of the Prefilled Safety Syringe or the Auto-injector for the Subcutaneous Self-injection of B

Trial registeredJun 18, 2020· ClinicalTrials.gov

Phase 3 trial registered on ClinicalTrials.gov: NCT04436640

A Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Bimekizumab in Subjects With Active Axial Spondyloarthritis Including

Trial startedJun 16, 2020· ClinicalTrials.gov

Phase 3 trial started: NCT04436640

A Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Bimekizumab in Subjects With Active Axial Spondyloarthritis Including

Primary completionMay 25, 2020· ClinicalTrials.gov

Phase 2 primary completion: NCT03215277

A Study to Test the Efficacy and Safety of Bimekizumab and Certolizumab Pegol in Patients With Active Ankylosing Spondylitis

Trial registeredApr 9, 2020· ClinicalTrials.gov

Phase 4 trial registered on ClinicalTrials.gov: NCT04340076

Dose Reduction of IL17 and IL23 Inhibitors in Psoriasis

Trial startedMar 2, 2020· ClinicalTrials.gov

Phase 3 trial started: NCT04242498

A Study to Evaluate the Efficacy and Safety of Bimekizumab in Study Participants With Moderate to Severe Hidradenitis Suppurativa

Trial startedFeb 19, 2020· ClinicalTrials.gov

Phase 3 trial started: NCT04242446

A Study to Evaluate the Efficacy and Safety of Bimekizumab in Study Participants With Moderate to Severe Hidradenitis Suppurativa

Trial startedFeb 12, 2020· ClinicalTrials.gov

Phase 1 trial started: NCT04255862

A Study to Evaluate the Bioequivalence of Bimekizumab Given as 1x2mL or 2x1mL Subcutaneous Injection in Healthy Study Participants

Trial registeredFeb 5, 2020· ClinicalTrials.gov

Phase 1 trial registered on ClinicalTrials.gov: NCT04255862

A Study to Evaluate the Bioequivalence of Bimekizumab Given as 1x2mL or 2x1mL Subcutaneous Injection in Healthy Study Participants

Trial registeredJan 27, 2020· ClinicalTrials.gov

Phase 3 trial registered on ClinicalTrials.gov: NCT04242498

A Study to Evaluate the Efficacy and Safety of Bimekizumab in Study Participants With Moderate to Severe Hidradenitis Suppurativa

Trial registeredJan 27, 2020· ClinicalTrials.gov

Phase 3 trial registered on ClinicalTrials.gov: NCT04242446

A Study to Evaluate the Efficacy and Safety of Bimekizumab in Study Participants With Moderate to Severe Hidradenitis Suppurativa

2019

Primary completionOct 4, 2019· ClinicalTrials.gov

Phase 1 primary completion: NCT03895385

A Study to Evaluate the Antibody Response of Influenza Vaccination Following Concomitant Exposure to Bimekizumab in Healthy Subjects

Trial registeredOct 1, 2019· ClinicalTrials.gov

Phase 3 trial registered on ClinicalTrials.gov: NCT04109976

A Study to Evaluate the Safe and Effective Use of the Prefilled Safety Syringe or the Auto-injector for the Subcutaneous Self-injection of B

Primary completionSep 12, 2019· ClinicalTrials.gov

Phase 3 primary completion: NCT03536884

A Study to Evaluate the Efficacy and Safety of Bimekizumab Compared to an Active Comparator in Adult Subjects With Moderate to Severe Chroni

Trial startedAug 13, 2019· ClinicalTrials.gov

Phase 3 trial started: NCT04109976

A Study to Evaluate the Safe and Effective Use of the Prefilled Safety Syringe or the Auto-injector for the Subcutaneous Self-injection of B

Trial startedAug 13, 2019· ClinicalTrials.gov

Phase 3 trial started: NCT04009499

A Study to Assess the Long-term Safety, Tolerability, and Efficacy of Bimekizumab in the Treatment of Subjects With Active Psoriatic Arthrit

Trial registeredJul 5, 2019· ClinicalTrials.gov

Phase 3 trial registered on ClinicalTrials.gov: NCT04009499

A Study to Assess the Long-term Safety, Tolerability, and Efficacy of Bimekizumab in the Treatment of Subjects With Active Psoriatic Arthrit

Primary completionJun 5, 2019· ClinicalTrials.gov

Phase 1 primary completion: NCT03707717

A Study to Compare the Blood Level of Bimekizumab Injected Subcutaneously Either by a Prefilled Syringe or by an Auto-injector in Adult Heal

Trial registeredApr 26, 2019· ClinicalTrials.gov

Phase 3 trial registered on ClinicalTrials.gov: NCT03928743

A Study to Evaluate the Efficacy and Safety of Bimekizumab in Subjects With Active Ankylosing Spondylitis

Trial registeredApr 26, 2019· ClinicalTrials.gov

Phase 3 trial registered on ClinicalTrials.gov: NCT03928704

A Study to Evaluate the Efficacy and Safety of Bimekizumab in Subjects With Active Nonradiographic Axial Spondyloarthritis

Trial startedApr 25, 2019· ClinicalTrials.gov

Phase 3 trial started: NCT03928743

A Study to Evaluate the Efficacy and Safety of Bimekizumab in Subjects With Active Ankylosing Spondylitis

Trial startedApr 25, 2019· ClinicalTrials.gov

Phase 3 trial started: NCT03928704

A Study to Evaluate the Efficacy and Safety of Bimekizumab in Subjects With Active Nonradiographic Axial Spondyloarthritis

Trial startedApr 3, 2019· ClinicalTrials.gov

Phase 3 trial started: NCT03895203

A Study to Test the Efficacy and Safety of Bimekizumab in the Treatment of Subjects With Active Psoriatic Arthritis

Trial startedApr 2, 2019· ClinicalTrials.gov

Phase 1 trial started: NCT03895385

A Study to Evaluate the Antibody Response of Influenza Vaccination Following Concomitant Exposure to Bimekizumab in Healthy Subjects

Trial registeredApr 1, 2019· ClinicalTrials.gov

Phase 3 trial registered on ClinicalTrials.gov: NCT03896581

A Study to Evaluate the Efficacy and Safety of Bimekizumab in the Treatment of Subjects With Active Psoriatic Arthritis

Trial registeredMar 29, 2019· ClinicalTrials.gov

Phase 3 trial registered on ClinicalTrials.gov: NCT03895203

A Study to Test the Efficacy and Safety of Bimekizumab in the Treatment of Subjects With Active Psoriatic Arthritis

Trial registeredMar 29, 2019· ClinicalTrials.gov

Phase 1 trial registered on ClinicalTrials.gov: NCT03895385

A Study to Evaluate the Antibody Response of Influenza Vaccination Following Concomitant Exposure to Bimekizumab in Healthy Subjects

Trial startedMar 28, 2019· ClinicalTrials.gov

Phase 3 trial started: NCT03896581

A Study to Evaluate the Efficacy and Safety of Bimekizumab in the Treatment of Subjects With Active Psoriatic Arthritis

Primary completionMar 6, 2019· ClinicalTrials.gov

Phase 2 primary completion: NCT03230292

A Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Bimekizumab in Adult Patients With Chronic Plaque Psoriasis

Primary completionFeb 7, 2019· ClinicalTrials.gov

Phase 3 primary completion: NCT03412747

A Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis

Primary completionJan 8, 2019· ClinicalTrials.gov

Phase 3 primary completion: NCT03370133

A Study to Evaluate the Efficacy and Safety of Bimekizumab Compared to Placebo and an Active Comparator in Adult Subjects With Moderate to S

2018

Primary completionDec 28, 2018· ClinicalTrials.gov

Phase 3 primary completion: NCT03410992

A Study With a Initial Treatment Period Followed by a Randomized-withdrawal Period to Evaluate the Efficacy and Safety of Bimekizumab in Adu

Trial startedDec 20, 2018· ClinicalTrials.gov

Phase 3 trial started: NCT03766685

A Study to Evaluate the Safe and Effective Use of the Prefilled Safety Syringe or the Auto-injector for the Subcutaneous Self-injection of B

Trial registeredDec 6, 2018· ClinicalTrials.gov

Phase 3 trial registered on ClinicalTrials.gov: NCT03766685

A Study to Evaluate the Safe and Effective Use of the Prefilled Safety Syringe or the Auto-injector for the Subcutaneous Self-injection of B

Primary completionNov 23, 2018· ClinicalTrials.gov

Phase 2 primary completion: NCT03248531

A Study to Test the Efficacy, Safety and Pharmacokinetics of Bimekizumab in Subjects With Moderate to Severe Hidradenitis Suppurativa.

Trial registeredOct 16, 2018· ClinicalTrials.gov

Phase 1 trial registered on ClinicalTrials.gov: NCT03707717

A Study to Compare the Blood Level of Bimekizumab Injected Subcutaneously Either by a Prefilled Syringe or by an Auto-injector in Adult Heal

Trial startedOct 15, 2018· ClinicalTrials.gov

Phase 1 trial started: NCT03707717

A Study to Compare the Blood Level of Bimekizumab Injected Subcutaneously Either by a Prefilled Syringe or by an Auto-injector in Adult Heal

Primary completionSep 25, 2018· ClinicalTrials.gov

Phase 2 primary completion: NCT03010527

A Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Bimekizumab in Patients With Chronic Plaque Psoriasis

Trial startedSep 5, 2018· ClinicalTrials.gov

Phase 3 trial started: NCT03598790

A Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis

Trial registeredJul 26, 2018· ClinicalTrials.gov

Phase 3 trial registered on ClinicalTrials.gov: NCT03598790

A Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis

Trial startedJun 13, 2018· ClinicalTrials.gov

Phase 3 trial started: NCT03536884

A Study to Evaluate the Efficacy and Safety of Bimekizumab Compared to an Active Comparator in Adult Subjects With Moderate to Severe Chroni

Trial registeredMay 25, 2018· ClinicalTrials.gov

Phase 3 trial registered on ClinicalTrials.gov: NCT03536884

A Study to Evaluate the Efficacy and Safety of Bimekizumab Compared to an Active Comparator in Adult Subjects With Moderate to Severe Chroni

Trial startedFeb 5, 2018· ClinicalTrials.gov

Phase 3 trial started: NCT03410992

A Study With a Initial Treatment Period Followed by a Randomized-withdrawal Period to Evaluate the Efficacy and Safety of Bimekizumab in Adu

Trial registeredJan 26, 2018· ClinicalTrials.gov

Phase 3 trial registered on ClinicalTrials.gov: NCT03412747

A Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis

Trial startedJan 26, 2018· ClinicalTrials.gov

Phase 3 trial started: NCT03412747

A Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis

Trial registeredJan 25, 2018· ClinicalTrials.gov

Phase 3 trial registered on ClinicalTrials.gov: NCT03410992

A Study With a Initial Treatment Period Followed by a Randomized-withdrawal Period to Evaluate the Efficacy and Safety of Bimekizumab in Adu

2017

Trial registeredDec 12, 2017· ClinicalTrials.gov

Phase 3 trial registered on ClinicalTrials.gov: NCT03370133

A Study to Evaluate the Efficacy and Safety of Bimekizumab Compared to Placebo and an Active Comparator in Adult Subjects With Moderate to S

Primary completionDec 11, 2017· ClinicalTrials.gov

Phase 2 primary completion: NCT03025542

A Study to Evaluate the Pharmacokinetics (PK), Pharmacodynamics (PD), and Safety of Bimekizumab in Patients With Chronic Plaque Psoriasis

Trial startedDec 6, 2017· ClinicalTrials.gov

Phase 3 trial started: NCT03370133

A Study to Evaluate the Efficacy and Safety of Bimekizumab Compared to Placebo and an Active Comparator in Adult Subjects With Moderate to S

Primary completionNov 30, 2017· ClinicalTrials.gov

Phase 2 primary completion: NCT02969525

A Study to Evaluate the Dose Response Based on the Efficacy, Safety and Tolerability of Bimekizumab in Subjects With Active Psoriatic Arthri

Trial registeredNov 28, 2017· ClinicalTrials.gov

Phase 2 trial registered on ClinicalTrials.gov: NCT03355573

A Study to Evaluate the Long Term Safety and Efficacy of Bimekizumab in Subjects With Ankylosing Spondylitis

Trial startedNov 28, 2017· ClinicalTrials.gov

Phase 2 trial started: NCT03355573

A Study to Evaluate the Long Term Safety and Efficacy of Bimekizumab in Subjects With Ankylosing Spondylitis

Trial startedNov 22, 2017· ClinicalTrials.gov

Phase 2 trial started: NCT03347110

A Study to Evaluate the Long-Term Safety and Efficacy of Bimekizumab in Subjects With Psoriatic Arthritis

Trial registeredNov 20, 2017· ClinicalTrials.gov

Phase 2 trial registered on ClinicalTrials.gov: NCT03347110

A Study to Evaluate the Long-Term Safety and Efficacy of Bimekizumab in Subjects With Psoriatic Arthritis

Primary completionOct 31, 2017· ClinicalTrials.gov

Phase 2 primary completion: NCT02963506

A Study to Evaluate the Efficacy and Safety of Different Doses of Bimekizumab in Subjects With Active Ankylosing Spondylitis

Trial startedOct 4, 2017· ClinicalTrials.gov

Phase 2 trial started: NCT03215277

A Study to Test the Efficacy and Safety of Bimekizumab and Certolizumab Pegol in Patients With Active Ankylosing Spondylitis

Trial startedSep 22, 2017· ClinicalTrials.gov

Phase 2 trial started: NCT03248531

A Study to Test the Efficacy, Safety and Pharmacokinetics of Bimekizumab in Subjects With Moderate to Severe Hidradenitis Suppurativa.

Trial registeredAug 14, 2017· ClinicalTrials.gov

Phase 2 trial registered on ClinicalTrials.gov: NCT03248531

A Study to Test the Efficacy, Safety and Pharmacokinetics of Bimekizumab in Subjects With Moderate to Severe Hidradenitis Suppurativa.

Trial registeredJul 26, 2017· ClinicalTrials.gov

Phase 2 trial registered on ClinicalTrials.gov: NCT03230292

A Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Bimekizumab in Adult Patients With Chronic Plaque Psoriasis

Trial registeredJul 12, 2017· ClinicalTrials.gov

Phase 2 trial registered on ClinicalTrials.gov: NCT03215277

A Study to Test the Efficacy and Safety of Bimekizumab and Certolizumab Pegol in Patients With Active Ankylosing Spondylitis

Trial startedJul 3, 2017· ClinicalTrials.gov

Phase 2 trial started: NCT03230292

A Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Bimekizumab in Adult Patients With Chronic Plaque Psoriasis

Primary completionJun 30, 2017· ClinicalTrials.gov

Phase 2 primary completion: NCT02905006

Study to Evaluate Safety and Efficacy of Different Doses of Bimekizumab in Patients With Chronic Plaque Psoriasis

Primary completionApr 30, 2017· ClinicalTrials.gov

Phase 2 primary completion: NCT02430909

Multiple Dose Study of UCB4940 as add-on to Certolizumab Pegol in Subjects With Rheumatoid Arthritis

Trial registeredJan 19, 2017· ClinicalTrials.gov

Phase 2 trial registered on ClinicalTrials.gov: NCT03025542

A Study to Evaluate the Pharmacokinetics (PK), Pharmacodynamics (PD), and Safety of Bimekizumab in Patients With Chronic Plaque Psoriasis

Trial registeredJan 5, 2017· ClinicalTrials.gov

Phase 2 trial registered on ClinicalTrials.gov: NCT03010527

A Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Bimekizumab in Patients With Chronic Plaque Psoriasis

2016

Trial startedDec 27, 2016· ClinicalTrials.gov

Phase 2 trial started: NCT03025542

A Study to Evaluate the Pharmacokinetics (PK), Pharmacodynamics (PD), and Safety of Bimekizumab in Patients With Chronic Plaque Psoriasis

Trial startedDec 14, 2016· ClinicalTrials.gov

Phase 2 trial started: NCT03010527

A Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Bimekizumab in Patients With Chronic Plaque Psoriasis

Trial registeredNov 21, 2016· ClinicalTrials.gov

Phase 2 trial registered on ClinicalTrials.gov: NCT02969525

A Study to Evaluate the Dose Response Based on the Efficacy, Safety and Tolerability of Bimekizumab in Subjects With Active Psoriatic Arthri

Trial registeredNov 15, 2016· ClinicalTrials.gov

Phase 2 trial registered on ClinicalTrials.gov: NCT02963506

A Study to Evaluate the Efficacy and Safety of Different Doses of Bimekizumab in Subjects With Active Ankylosing Spondylitis

Trial startedOct 31, 2016· ClinicalTrials.gov

Phase 2 trial started: NCT02963506

A Study to Evaluate the Efficacy and Safety of Different Doses of Bimekizumab in Subjects With Active Ankylosing Spondylitis

Trial startedOct 31, 2016· ClinicalTrials.gov

Phase 2 trial started: NCT02969525

A Study to Evaluate the Dose Response Based on the Efficacy, Safety and Tolerability of Bimekizumab in Subjects With Active Psoriatic Arthri

Trial registeredSep 19, 2016· ClinicalTrials.gov

Phase 2 trial registered on ClinicalTrials.gov: NCT02905006

Study to Evaluate Safety and Efficacy of Different Doses of Bimekizumab in Patients With Chronic Plaque Psoriasis

Trial startedAug 31, 2016· ClinicalTrials.gov

Phase 2 trial started: NCT02905006

Study to Evaluate Safety and Efficacy of Different Doses of Bimekizumab in Patients With Chronic Plaque Psoriasis

Primary completionJun 17, 2016· ClinicalTrials.gov

Phase 1 primary completion: NCT05028127

A Study to Evaluate the Relative Bioavailability and Tolerability of Bimekizumab in Healthy Subjects

Trial startedMar 4, 2016· ClinicalTrials.gov

Phase 1 trial started: NCT05028127

A Study to Evaluate the Relative Bioavailability and Tolerability of Bimekizumab in Healthy Subjects

2015

Trial startedApr 30, 2015· ClinicalTrials.gov

Phase 2 trial started: NCT02430909

Multiple Dose Study of UCB4940 as add-on to Certolizumab Pegol in Subjects With Rheumatoid Arthritis

Trial registeredApr 30, 2015· ClinicalTrials.gov

Phase 2 trial registered on ClinicalTrials.gov: NCT02430909

Multiple Dose Study of UCB4940 as add-on to Certolizumab Pegol in Subjects With Rheumatoid Arthritis

Sources

FDA approvals, label revisions, and recalls come from the public openFDA APIs (Drugs@FDA, Drug Label, Drug Enforcement). Drug-safety communications come from the FDA RSS feed. Trial milestones come from ClinicalTrials.gov via the AACT pg dump. Pivotal-publication events come from PubMed, filtered to high-impact journals linked to a Phase 3 trial in our inventory.